Marrone Bio Innovations Inc., a Davis-based, international leader in sustainable bioprotection and plant health solutions, received notice from the Nasdaq stock market on June 19 indicating that the company regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.
Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1 per share.
“We are pleased to announce to our shareholders that the company has regained full compliance with Nasdaq’s continued listing requirements,” said Pam Marrone, founder and chief executive officer of Marrone Bio Innovations. “With this matter now resolved, our officers and directors will continue to remain focused on driving growth and creating sustainable shareholder value over the long term.”
MBI closed on Friday, June 26, at $1.04 per share.ShareTweet